A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders

Neuromyelitis Optica Spectrum Disorders Clinical Trial

Official title:

A Phase III Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Neuromyelitis Optica Spectrum Disorders.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03330418
• Other study ID #: C009NMOSDCLLI
• Status: Recruiting
• Phase: Phase 3
• Start date: January 29, 2018
• Est. completion date: December 2025

Study information

• Verified date: November 2023
• Source: RemeGen Co., Ltd.
• Contact: Binghua Xiao
• Phone: 86-010-58076833
• Email: xiaosir522[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with Neuromyelitis Optica Spectrum Disorders.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 166
• Est. completion date: December 2025
• Est. primary completion date: May 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Meet the 2015 international consensus diagnostic criteria for Neuromyelitis Optica Spectrum Disorders and astrocyte water channel aquaporin-4 (AQP4) antibody positivity.
• EDSS 0-7.5
• Clinical evidence of at least 2 relapses within the first two years of randomization and/ or 1 relapse within the first one year of randomization
• Consent to use effective contraception during the study period (women of childbearing age)
• Voluntarily signed informed consent

Exclusion Criteria:

• Abnormal laboratory parameters need to be excluded, including but not limited to:
• Currently suffering from active hepatitis or serious liver disease and medical history
• Patients were treated with rituximab or other monoclonal antibodies within 6 months prior to randomization .
• Any concomitant disease other than neuromyelitis optica(NMO)/ neuromyelitis optica Spectrum disorders(NMOSD)that required treatment with lucocorticoid.
• pregnant , lactating women and men or women who have birth plans during the research;
• Have a history of allergic reaction to contrast agent for parenteral administration and human biological medicines.
• Receipt of intravenous immune globulin ( IVIG) within 28 days prior to randomization.
• Receipt of any of the following prior to randomization: Azathioprine,Cyclosporin, Methotrexate Mitoxantrone,Cyclophosphamide,Tocilizumab,Tacrolimus,Mycophenolate,and Patients discontinued more than 5 times the half-life of the drug before they could get into the group .If the patients taking leflunomide and teriflunomide,they should need to take colestyramine for elution.
• Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking shorter time ).
• The patients have severe psychiatric symptoms and are not compatible with clinical studies
• Malignant tumor patients ;
• patients experienced any of the following events within 12 weeks before screening :

myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association class IV heart failure

• Patients can't accept magnetic resonance imaging inspection during the trial.
• Infection with herpes zoster or HIV virus at the screening;
• The anti-hepatitis C virus (anti-HCV) of patients show positive;
• Investigator considers candidates not appropriating for the study.

Related Conditions & MeSH terms

• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorders

Intervention

Biological:
• Placebo
Starting with the forty-ninth dose,the trial went into the open phase. All participants were treated with the test drugs.
• RC18 160 mg
In the Phase B,the researchers can adjust the dose of RC18 according to the subjects' willingness and recurrence, but the maximum dose of single dose should not exceed 320g.

Locations

Country	Name	City	State
China	Beijing Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
RemeGen Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to first relapse after randomization		144 weeks
Secondary	Change from Baseline in Expanded Disability Status Scale (EDSS) Score at week 4,8,12,24,36,48,60,72,96,120,144	The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death) in half-point increments.	144 weeks
Secondary	Change from Baseline in Hauser Ambulation Index at week 4,8,12,24,36,48,60,72,96,120,144		week 4,8,12,24,36,48,60,72,96,120,144